OpEd In New Jersey Star Ledger, State’s Largest Paper. In a guest column for the New Jersey Star-Ledger, a former White House spokesman and Chief-of-Staff for the House Aging Committee and Health Subcommittee, Robert Weiner, a George Washington University breast cancer laboratory director and professor, Dr. Patricia Berg, and policy analyst, James Lewis assert that “as the government keeps funding two wars and ongoing tax breaks, curing diseases like cancer is being threatened in the budget debates underway. In both the State of the Union and Budget Message, President Obama promised investment in biomedical research. However, House Appropriations Chairman Harold Rogers (R-KY) just announced that his proposed House budget has a $1 Billion cut in NIH funding.”
Weiner, Berg, and Lewis contend, “Research cuts could mean ongoing cancer deaths. The nation is almost schizophrenic between cuts and necessary programs. With the economy still in crisis, the private sector does not have the ability to make up the difference.
“One in two men and one in three women will develop cancer in their lifetime, according to the National Cancer Institute. In 2010, there were 1.5 million new cancer cases and 570,000 deaths in the U.S. In just breast cancer alone, NCI estimated 209,060 new breast cancer patients and 40,230 deaths last year.
“The good news is that thanks to successful laboratory research, a woman’s risk of dying of breast cancer has now dropped 31 percent since 1989.” The authors cite Dr. Francis Collins, Director of the National Institute of Health (NIH), who told the National Press Club, “There is a direct line from NIH research to the life-span increases in America.” But Weiner, Berg, and Lewis point out, “Despite these breakthroughs, the U.S. now ranks 49th in life expectancy, right above Taiwan, Kuwait, Cyprus, Cuba, Panama, and Costa Rica.
“While such clear breakthroughs are being made—and with breast cancer still ranking as the number one fear for women – now is no time to stop the train and cut funding.
“If government funding does drop or stalemate, cutting-edge researchers will have to seek even more funding from private foundations and corporations, trying to fill the void.
“And they do try. For example, the Avon Foundation, one of the largest corporate-affiliated philanthropies contributing to breast cancer research, has donated over 700 million dollars to breast cancer education, research, and prevention since 1992, and over 175 million to research in the last decade. Avon expedites tests and advancement of cutting-edge discoveries with significant diagnosis and treatment potential like Beta Protein 1, a gene discovered by Berg which is expressed in the tumors of 80% of women with breast cancer and 70% of men with prostate cancer. Susan G. Komen for the Cure, Revlon, and the Susan Love Research Foundation and Love/Army of Women, also help make up the difference. The Robert Wood Johnson Foundation has been ‘one of the key funding agencies’ for the Cancer Institute of New Jersey, the state’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center.
“In the world’s wealthiest nation, with a government funding cut threatened, private industries are scrambling to fund live-saving research.
“The future of the new national health care law, which provides free preventive care that detects cancer early when it is more curable and could catch Stage I cancers before they develop into Stage IV, is also under fire. The future is uncertain. We are in a budget-cutting spree.
“Under President Clinton and under the Obama stimulus, NIH’s budget doubled, but efforts to maintain the Iraq and Afghanistan Wars and the political insistence on tax cuts are now creating a fear throughout the research field that medical research funding will be sliced. To keep the breakthroughs and research going strong, the public must support cancer research foundations — and press Congress to halt its efforts to dry up federal research dollars. If we want to fight cancer, and win, there is no substitute for the federal catalyst.”
Source : Robert Weiner Associates